Your cart is empty
Have an account? Log in to check out faster.
Have an account? Log in to check out faster.
Premium PDF Edition — One-time purchase. No Kindle Unlimited subscription needed.
| Language | English |
| Format | PDF (Premium Digital) |
| Ownership | Permanent download — yours forever |
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents by J Morganroth
The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.| SKU | NLS9781461288886 |
|---|---|
| ISBN 13 | 9781461288886 |
| ISBN 10 | 1461288886 |
| Author | J Morganroth |
| Series | Developments In Cardiovascular Medicine |
| Condition | New |
| Binding Type | Paperback |
| Publisher | Springer-Verlag New York Inc. |
| Year published | 2011-10-10 |
| Number of pages | 298 |
| Cover note | Book picture is for illustrative purposes only, actual binding, cover or edition may vary. |
"I was paying $11.99/month for Kindle Unlimited but realized I was renting books, not owning them. Bought this PDF and it's mine forever. Never going back to Kindle."
"Switched from Kindle to these PDFs. Same book, but I actually OWN it now. No monthly fees, no app required. Worth every penny."
"Kindle Unlimited kept raising prices. This is a one-time purchase and the file is permanently on my iPad. Best decision I've made for my reading habit."
"I compared Kindle vs this store. Kindle is cheaper monthly but you don't own anything. Here I paid once and the PDF is mine for life. Highly recommend."
"Left Kindle behind after they removed a book I was reading mid-series. With this PDF, nobody can take it away from me. True ownership feels good."
"Was skeptical about paying $18.95 when Kindle shows $3.99, but then I did the math — Kindle Unlimited is $143/year! This is way better value long term."
"Love that I can read this on any device without installing the Kindle app. The PDF works on my laptop, phone, and tablet seamlessly. So much freedom."
"My Kindle subscription was getting expensive. Switched to buying PDFs here and I'm saving money while actually building a permanent digital library I control."
"I was paying $11.99/month for Kindle Unlimited but realized I was renting books, not owning them. Bought this PDF and it's mine forever. Never going back to Kindle."
"Switched from Kindle to these PDFs. Same book, but I actually OWN it now. No monthly fees, no app required. Worth every penny."
"Kindle Unlimited kept raising prices. This is a one-time purchase and the file is permanently on my iPad. Best decision I've made for my reading habit."
"I compared Kindle vs this store. Kindle is cheaper monthly but you don't own anything. Here I paid once and the PDF is mine for life. Highly recommend."
"Left Kindle behind after they removed a book I was reading mid-series. With this PDF, nobody can take it away from me. True ownership feels good."
"Was skeptical about paying $18.95 when Kindle shows $3.99, but then I did the math — Kindle Unlimited is $143/year! This is way better value long term."
"Love that I can read this on any device without installing the Kindle app. The PDF works on my laptop, phone, and tablet seamlessly. So much freedom."
"My Kindle subscription was getting expensive. Switched to buying PDFs here and I'm saving money while actually building a permanent digital library I control."
$0
Zero monthly fees. Pay once, own forever. Unlike Kindle Unlimited at $11.99/month.
100%
True ownership. Your PDF cannot be revoked, removed, or locked behind a subscription.
Anywhere
No Kindle app required. Read on any device with any PDF reader — even offline forever.
Save
Cheaper than Amazon paperback. Better value than Kindle Unlimited long-term.